Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immune-related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-world Data

Version 1 : Received: 29 May 2021 / Approved: 31 May 2021 / Online: 31 May 2021 (12:49:40 CEST)

A peer-reviewed article of this Preprint also exists.

Chan, W.-L.; Choi, H.C.-W.; Ho, P.P.-Y.; Lau, J.K.-S.; Tse, R.P.-Y.; Au, J.; Lam, V.; Liu, R.; Ho, I.; Wong, C.; Cheung, B.; Lam, E.; Chow, D.; Lam, K.-O.; Yuen, K.-K.; Kwong, D.L.-W. Immune-Related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-World Data. Cancers 2021, 13, 3797. Chan, W.-L.; Choi, H.C.-W.; Ho, P.P.-Y.; Lau, J.K.-S.; Tse, R.P.-Y.; Au, J.; Lam, V.; Liu, R.; Ho, I.; Wong, C.; Cheung, B.; Lam, E.; Chow, D.; Lam, K.-O.; Yuen, K.-K.; Kwong, D.L.-W. Immune-Related Endocrine Dysfunctions in Combined Modalities of Treatment: Real-World Data. Cancers 2021, 13, 3797.

Journal reference: Cancers 2021, 13, 3797
DOI: 10.3390/cancers13153797

Abstract

Abstract Background The number of immune-related endocrine dysfunctions (irEDs) has concurrently increased with the widespread use of immunotherapy in clinical practice and further expansion of the approved indications for immune checkpoint inhibitor (ICI) combinations using different modalities of anti-cancer treatment. Method A retrospective analysis was conducted on consecutive patients >18 years of age with advanced solid malignancies who had received at least one dose of anti-programmed cell death protein 1 (anti-PD-1) and/or anti-CTLA4 antibodies between January 2014 and December 2019 at a Hong Kong university hospital. Patients were reviewed for up to two months after the last administration of an ICI. The types, onset times and grades of irEDs, including hypothyroidism, hyperthyroidism, adrenal insufficiency and immune-related diabetes mellitus, were recorded. Factors associated with irEDs were identified using multivariate analysis. Result A total of 953 patients (male: 603, 64.0%; median age: 62.0 years) received ICIs during the study period. Of these, 580 patients (60.9%) used ICI-alone, 132 (13.9%) used dual-ICI, 187 (19.6%) used an ICI combined with chemotherapy (chemo+ICI), and 54 (5.70%) used immunotherapy with a targeted agent (targeted+ICI). A significantly higher proportion of patients using targeted+ICI had irEDs and hypothyroidism; in contrast, a higher proportion of patients using dual-ICI had adrenal insufficiency. There was no significant difference in the incidence of irED between the younger (<65 years) and older (>65 years) patients. Using logistic regression, only treatment type was significantly associated with irEDs. Notably, older patients had a higher risk of having immune-related diabetes mellitus. Conclusions This large, real-world cohort demonstrates that combining ICI with targeted therapy has a higher risk of overall irED and hypothyroidism. Immunotherapy is safe and well-tolerated regardless of age, but close monitoring of fasting glucose is needed in older populations.

Keywords

Immune checkpoint inhibitors; immune-related endocrine dysfunction; hypothyroidism; targeted therapy; malignancy

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.